Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Identification of Human Toll-like Receptor 2-Agonistic Activity in Dihydropyridine-Quinolone Carboxamides.

Hu Z, Banothu J, Beesu M, Gustafson CJ, Brush MJH, Trautman KL, Salyer ACD, Pathakumari B, David SA.

ACS Med Chem Lett. 2018 Dec 20;10(1):132-136. doi: 10.1021/acsmedchemlett.8b00540. eCollection 2019 Jan 10.

PMID:
30655960
2.

Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands.

Zhang Z, Ohto U, Shibata T, Taoka M, Yamauchi Y, Sato R, Shukla NM, David SA, Isobe T, Miyake K, Shimizu T.

Cell Rep. 2018 Dec 18;25(12):3371-3381.e5. doi: 10.1016/j.celrep.2018.11.081.

3.

In vitro Analysis of Shear Bond Strength and Adhesive Remnant Index of Stainless Steel Brackets with Different Adhesive Systems to Enamel.

Vaheed NA, Gupta M, David SA, Sam G, Ramanna PK, Bhagvandas SC.

J Contemp Dent Pract. 2018 Sep 1;19(9):1047-1051.

PMID:
30287702
4.

Lymph-Node-Targeted Immune Activation by Engineered Block Copolymer Amphiphiles-TLR7/8 Agonist Conjugates.

Van Herck S, Deswarte K, Nuhn L, Zhong Z, Portela Catani JP, Li Y, Sanders NN, Lienenklaus S, De Koker S, Lambrecht BN, David SA, De Geest BG.

J Am Chem Soc. 2018 Oct 31;140(43):14300-14307. doi: 10.1021/jacs.8b08595. Epub 2018 Oct 17.

PMID:
30277761
5.

Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses.

Nuhn L, De Koker S, Van Lint S, Zhong Z, Catani JP, Combes F, Deswarte K, Li Y, Lambrecht BN, Lienenklaus S, Sanders NN, David SA, Tavernier J, De Geest BG.

Adv Mater. 2018 Nov;30(45):e1803397. doi: 10.1002/adma.201803397. Epub 2018 Oct 1.

PMID:
30276880
6.

APSI scaphoid hemiarthroplasty - long-term results.

Santos FL, Ferreira A, Grazina R, Sá D, Canela P, Lemos R.

Rev Bras Ortop. 2018 Aug 2;53(5):582-588. doi: 10.1016/j.rboe.2018.07.011. eCollection 2018 Sep-Oct.

7.

Hyaluronic Acid Conjugates of TLR7/8 Agonists for Targeted Delivery to Secondary Lymphoid Tissue.

Yoo E, Salyer ACD, Brush MJH, Li Y, Trautman KL, Shukla NM, De Beuckelaer A, Lienenklaus S, Deswarte K, Lambrecht BN, De Geest BG, David SA.

Bioconjug Chem. 2018 Aug 15;29(8):2741-2754. doi: 10.1021/acs.bioconjchem.8b00386. Epub 2018 Jul 17.

PMID:
29969553
8.

Transcriptomal signatures of vaccine adjuvants and accessory immunostimulation of sentinel cells by toll-like receptor 2/6 agonists.

Salyer ACD, David SA.

Hum Vaccin Immunother. 2018 Jul 3;14(7):1686-1696. doi: 10.1080/21645515.2018.1480284. Epub 2018 Jun 20.

9.

Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist.

Nuhn L, Van Hoecke L, Deswarte K, Schepens B, Li Y, Lambrecht BN, De Koker S, David SA, Saelens X, De Geest BG.

Biomaterials. 2018 Sep;178:643-651. doi: 10.1016/j.biomaterials.2018.03.026. Epub 2018 Mar 16.

PMID:
29573820
10.

Transiently Thermoresponsive Acetal Polymers for Safe and Effective Administration of Amphotericin B as a Vaccine Adjuvant.

Van Herck S, Van Hoecke L, Louage B, Lybaert L, De Coen R, Kasmi S, Esser-Kahn AP, David SA, Nuhn L, Schepens B, Saelens X, De Geest BG.

Bioconjug Chem. 2018 Mar 21;29(3):748-760. doi: 10.1021/acs.bioconjchem.7b00641. Epub 2017 Dec 13.

PMID:
29172458
11.

An Assessment of Fixed and Native Chromatin Preparation Methods to Study Histone Post-Translational Modifications at a Whole Genome Scale in Skeletal Muscle Tissue.

David SA, Piégu B, Hennequet-Antier C, Pannetier M, Aguirre-Lavin T, Crochet S, Bordeau T, Couroussé N, Brionne A, Bigot Y, Collin A, Coustham V.

Biol Proced Online. 2017 Aug 29;19:10. doi: 10.1186/s12575-017-0059-0. eCollection 2017.

12.

An Innovative Approach to Retention: Thermoplastic Retainer.

Ozeer KAA, David SA, Mohamed U, Sunil PC, Paul S, Paul P.

J Contemp Dent Pract. 2017 Jul 1;18(7):572-575.

PMID:
28713110
13.

Congenital kinking of aorta.

Thodi Ramamurthy M, Balakrishnan VK, David SAN, Korrapati HS.

BMJ Case Rep. 2017 Jul 13;2017. pii: bcr-2017-220896. doi: 10.1136/bcr-2017-220896.

14.

Gene Resistance to Transcriptional Reprogramming following Nuclear Transfer Is Directly Mediated by Multiple Chromatin-Repressive Pathways.

Jullien J, Vodnala M, Pasque V, Oikawa M, Miyamoto K, Allen G, David SA, Brochard V, Wang S, Bradshaw C, Koseki H, Sartorelli V, Beaujean N, Gurdon J.

Mol Cell. 2017 Mar 2;65(5):873-884.e8. doi: 10.1016/j.molcel.2017.01.030.

15.

Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.

Beesu M, Salyer AC, Brush MJ, Trautman KL, Hill JK, David SA.

J Med Chem. 2017 Mar 9;60(5):2084-2098. doi: 10.1021/acs.jmedchem.6b01860. Epub 2017 Feb 15.

PMID:
28146629
16.

Urologist Use of Cystoscopy for Patients Presenting With Hematuria in the United States.

David SA, Patil D, Alemozaffar M, Issa MM, Master VA, Filson CP.

Urology. 2017 Feb;100:20-26. doi: 10.1016/j.urology.2016.09.018. Epub 2016 Sep 16.

PMID:
27645524
17.

Syntheses of Human TLR8-Specific Small-Molecule Agonists.

Beesu M, Kokatla HP, David SA.

Methods Mol Biol. 2017;1494:29-44.

PMID:
27718184
18.

Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines.

Beesu M, Salyer AC, Trautman KL, Hill JK, David SA.

J Med Chem. 2016 Sep 8;59(17):8082-93. doi: 10.1021/acs.jmedchem.6b00872. Epub 2016 Aug 19.

PMID:
27513008
19.

Implementation of a Tele-urology Program for Outpatient Hematuria Referrals: Initial Results and Patient Satisfaction.

Safir IJ, Gabale S, David SA, Huang JH, Gerhard RS, Pearl J, Lorentz CA, Baumgardner J, Filson CP, Issa MM.

Urology. 2016 Nov;97:33-39. doi: 10.1016/j.urology.2016.04.066. Epub 2016 Jul 19.

PMID:
27450940
20.

pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation.

Nuhn L, Vanparijs N, De Beuckelaer A, Lybaert L, Verstraete G, Deswarte K, Lienenklaus S, Shukla NM, Salyer AC, Lambrecht BN, Grooten J, David SA, De Koker S, De Geest BG.

Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8098-103. doi: 10.1073/pnas.1600816113. Epub 2016 Jul 5.

21.

Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.

Beesu M, Caruso G, Salyer AC, Shukla NM, Khetani KK, Smith LJ, Fox LM, Tanji H, Ohto U, Shimizu T, David SA.

J Med Chem. 2016 Apr 14;59(7):3311-30. doi: 10.1021/acs.jmedchem.6b00023. Epub 2016 Mar 22.

PMID:
26966993
22.

Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.

Salyer AC, Caruso G, Khetani KK, Fox LM, Malladi SS, David SA.

PLoS One. 2016 Feb 26;11(2):e0149848. doi: 10.1371/journal.pone.0149848. eCollection 2016.

23.

Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.

Beesu M, Caruso G, Salyer AC, Khetani KK, Sil D, Weerasinghe M, Tanji H, Ohto U, Shimizu T, David SA.

J Med Chem. 2015 Oct 8;58(19):7833-49. doi: 10.1021/acs.jmedchem.5b01087. Epub 2015 Sep 22.

24.

The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes.

Ganapathi L, Van Haren S, Dowling DJ, Bergelson I, Shukla NM, Malladi SS, Balakrishna R, Tanji H, Ohto U, Shimizu T, David SA, Levy O.

PLoS One. 2015 Aug 14;10(8):e0134640. doi: 10.1371/journal.pone.0134640. eCollection 2015.

25.

Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.

Samuels BA, Mendez-David I, Faye C, David SA, Pierz KA, Gardier AM, Hen R, David DJ.

Neuroscientist. 2016 Feb;22(1):26-45. doi: 10.1177/1073858414561303. Epub 2014 Dec 8. Review.

26.

Determinants of activity at human Toll-like receptors 7 and 8: quantitative structure-activity relationship (QSAR) of diverse heterocyclic scaffolds.

Yoo E, Salunke DB, Sil D, Guo X, Salyer AC, Hermanson AR, Kumar M, Malladi SS, Balakrishna R, Thompson WH, Tanji H, Ohto U, Shimizu T, David SA.

J Med Chem. 2014 Oct 9;57(19):7955-70. doi: 10.1021/jm500744f. Epub 2014 Sep 17.

27.

Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.

Beesu M, Malladi SS, Fox LM, Jones CD, Dixit A, David SA.

J Med Chem. 2014 Sep 11;57(17):7325-41. doi: 10.1021/jm500701q. Epub 2014 Aug 20.

28.

Detecting Tie2, an endothelial growth factor receptor, by using immunohistochemistry in mouse lungs.

Guha PP, David SA, Ghosh CC.

Methods Mol Biol. 2014;1172:201-8. doi: 10.1007/978-1-4939-0928-5_18.

PMID:
24908307
29.

Structure-based design of novel human Toll-like receptor 8 agonists.

Kokatla HP, Sil D, Tanji H, Ohto U, Malladi SS, Fox LM, Shimizu T, David SA.

ChemMedChem. 2014 Apr;9(4):719-23. doi: 10.1002/cmdc.201300573. Epub 2014 Jan 28.

30.

Biophysical mechanisms of the neutralization of endotoxins by lipopolyamines.

Sil D, Heinbockel L, Kaconis Y, Rössle M, Garidel P, Gutsmann T, David SA, Brandenburg K.

Open Biochem J. 2013 Sep 30;7:82-93. doi: 10.2174/1874091X01307010082. eCollection 2013.

31.

Structure-activity relationships in Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines.

Yoo E, Crall BM, Balakrishna R, Malladi SS, Fox LM, Hermanson AR, David SA.

Org Biomol Chem. 2013 Oct 14;11(38):6526-45. doi: 10.1039/c3ob40816g. Epub 2013 Aug 23.

PMID:
23974333
32.

Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Kokatla HP, Sil D, Malladi SS, Balakrishna R, Hermanson AR, Fox LM, Wang X, Dixit A, David SA.

J Med Chem. 2013 Sep 12;56(17):6871-85. doi: 10.1021/jm400694d. Epub 2013 Aug 15.

33.

Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants.

Salunke DB, Connelly SW, Shukla NM, Hermanson AR, Fox LM, David SA.

J Med Chem. 2013 Jul 25;56(14):5885-900. doi: 10.1021/jm400620g. Epub 2013 Jul 10.

34.

Multiple outbreaks of a novel norovirus GII.4 linked to an infected post-symptomatic food handler.

Thornley CN, Hewitt J, Perumal L, Van Gessel SM, Wong J, David SA, Rapana JP, Li S, Marshall JC, Greening GE.

Epidemiol Infect. 2013 Aug;141(8):1585-97. doi: 10.1017/S0950268813000095. Epub 2013 Feb 6.

PMID:
23388349
35.

Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines.

Kokatla HP, Yoo E, Salunke DB, Sil D, Ng CF, Balakrishna R, Malladi SS, Fox LM, David SA.

Org Biomol Chem. 2013 Feb 21;11(7):1179-98. doi: 10.1039/c2ob26705e.

36.

Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer.

Shukla NM, Salunke DB, Balakrishna R, Mutz CA, Malladi SS, David SA.

PLoS One. 2012;7(8):e43612. doi: 10.1371/journal.pone.0043612. Epub 2012 Aug 28.

37.

Antibacterial activities of Groebke-Blackburn-Bienaymé-derived imidazo[1,2-a]pyridin-3-amines.

Shukla NM, Salunke DB, Yoo E, Mutz CA, Balakrishna R, David SA.

Bioorg Med Chem. 2012 Oct 1;20(19):5850-63. doi: 10.1016/j.bmc.2012.07.052. Epub 2012 Aug 8.

38.

Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.

Salunke DB, Yoo E, Shukla NM, Balakrishna R, Malladi SS, Serafin KJ, Day VW, Wang X, David SA.

J Med Chem. 2012 Sep 27;55(18):8137-51. Epub 2012 Sep 7.

39.

Antimicrobial peptides for gram-negative sepsis: a case for the polymyxins.

David SA.

Front Immunol. 2012 Aug 15;3:252. doi: 10.3389/fimmu.2012.00252. eCollection 2012. No abstract available.

40.

Bacterial cell wall compounds as promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines.

Martínez de Tejada G, Sánchez-Gómez S, Rázquin-Olazaran I, Kowalski I, Kaconis Y, Heinbockel L, Andrä J, Schürholz T, Hornef M, Dupont A, Garidel P, Lohner K, Gutsmann T, David SA, Brandenburg K.

Curr Drug Targets. 2012 Aug;13(9):1121-30.

41.

Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.

Salunke DB, Shukla NM, Yoo E, Crall BM, Balakrishna R, Malladi SS, David SA.

J Med Chem. 2012 Apr 12;55(7):3353-63. doi: 10.1021/jm3000533. Epub 2012 Mar 15.

42.

Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.

Shukla NM, Mutz CA, Malladi SS, Warshakoon HJ, Balakrishna R, David SA.

J Med Chem. 2012 Feb 9;55(3):1106-16. doi: 10.1021/jm2010207. Epub 2012 Jan 27.

43.

Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.

Ukani R, Lewis TC, Day TP, Wu W, Malladi SS, Warshakoon HJ, David SA.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):293-5. doi: 10.1016/j.bmcl.2011.11.014. Epub 2011 Nov 9.

44.

Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides.

Agnihotri G, Crall BM, Lewis TC, Day TP, Balakrishna R, Warshakoon HJ, Malladi SS, David SA.

J Med Chem. 2011 Dec 8;54(23):8148-60. doi: 10.1021/jm201071e. Epub 2011 Nov 4.

45.

Evaluation of growth based rapid microbiological methods for sterility testing of vaccines and other biological products.

Parveen S, Kaur S, David SA, Kenney JL, McCormick WM, Gupta RK.

Vaccine. 2011 Oct 19;29(45):8012-23. doi: 10.1016/j.vaccine.2011.08.055. Epub 2011 Aug 24.

PMID:
21871516
46.

Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.

Shukla NM, Malladi SS, Day V, David SA.

Bioorg Med Chem. 2011 Jun 15;19(12):3801-11. doi: 10.1016/j.bmc.2011.04.052. Epub 2011 May 1.

47.

Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.

Shukla NM, Lewis TC, Day TP, Mutz CA, Ukani R, Hamilton CD, Balakrishna R, David SA.

Bioorg Med Chem Lett. 2011 Jun 1;21(11):3232-6. doi: 10.1016/j.bmcl.2011.04.050. Epub 2011 Apr 20.

48.

Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic γ-glutamyldiaminopimelic acid derivatives.

Agnihotri G, Ukani R, Malladi SS, Warshakoon HJ, Balakrishna R, Wang X, David SA.

J Med Chem. 2011 Mar 10;54(5):1490-510. doi: 10.1021/jm101535e. Epub 2011 Feb 7.

49.

Extrapulmonary tuberculosis: importance of differential diagnosis.

Mota PC, Sá D, Mota M, Duarte R.

BMJ Case Rep. 2011 Sep 19;2011. pii: bcr0620114363. doi: 10.1136/bcr.06.2011.4363.

50.

Imbuing aqueous solubility to amphotericin B and nystatin with a vitamin.

Day TP, Sil D, Shukla NM, Anbanandam A, Day VW, David SA.

Mol Pharm. 2011 Feb 7;8(1):297-301. doi: 10.1021/mp100363f. Epub 2010 Dec 17.

Supplemental Content

Loading ...
Support Center